AEterna Zentaris Inc. (T:AEZS)
Business Focus: Biotechnology & Medical Research (NEC)
| This company is also listed in the United States as AEZS on the NASDAQ. Click here to get the live US quote and see if there are any SEC insider filings.. |
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| Company Contact | |
| Address: | 315 Sigma Drive SUMMERVILLE NB 29486 |
| Tel: | N/A |
| Website: | https://www.zentaris.com |
| IR: | See website |
| Key People | ||
| Klaus Paulini President, Chief Executive Officer, Director and Managing Director - AEZS Germany | Giuliano La Fratta Chief Financial Officer, Senior Vice President | Michael E. B. Teifel Senior Vice President - Non-Clinical Development, Chief Scientific Officer |
| Nicola Ammer Senior Vice President - Clinical Development, Chief Medical Officer | Matthias Gerlach Senior Vice President - Manufacturing and Supply Chain | Eckhard G. Gunther Senior Vice President - Business Development and Alliance Management, Managing Director - Aeterna Zentaris GmbH |
| Business Overview |
| Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, AEterna Zentaris Inc. revenues decreased 20% to $4.5M. Net loss decreased 27% to $16.6M. Revenues reflect Switzerland segment decrease of 20% to $4.3M, Denmark segment decrease of 93% to $11K. Lower net loss reflects Impairment of goodwill decrease from $7.6M (expense) to $0K, Impairment of Intangibles Excl Goodwill decrease from $584K (expense) to $0K. |
| Employees: | 21 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | N/A |
| Annual revenue (TTM): | $6.19M as of Dec 31, 2023 |
| EBITDA (TTM): | -$24.56M as of Dec 31, 2023 |
| Net annual income (TTM): | -$22.79M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$23.60M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 4,855,876 as of Mar 26, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
